CROI Conference 2021

6-7 March 2021 - Virtual Congress

At the 28th edition of the Conference on Human Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented amongst others, abstracts around some of the latest findings and progress being made on HIV/AIDS research.

ViiV Abstracts for CROI 2021

Abstract title
Inflammatory and atherogenesis markers 148 weeks post-switch to DTG + RPV in SWORD-1/-2
Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a
TAF-based regimen (TBR) through 96 weeks: subgroup analyses from the TANGO study
Durable efficacy of DTG + 3TC in GEMINI-1&-2: year 3 subgroup analyses
Association between newer antiretrovirals and increase in body mass index in RESPOND
Association between integrase inhibitors (INSTIs) and cardiovascular disease
Cabotegravir PPK simulation to inform Q2M strategies following dosing interruptions
Weight and lipid changes in phase 3 cabotegravir and rilpivirine long-acting trials
Long-acting cabotegravir + rilpivirine in older adults: pooled phase 3 Week 48 results
Week 96 efficacy and safety of cabotegravir + rilpivirine every 2 months: ATLAS-2M
Renal/bone outcomes after long-acting cabotegravir + rilpivirine in ATLAS + ATLAS-2M
PopPK modelling of Q2M IM RPV LA for managing dosing interruptions in HIV-1 patients
Reduced susceptibility to temsavir is not linked to IBA or MVC resistance
Randomised Controlled Trial (RCT) of an online mental health intervention among older PLWH during
COVID-19 pandemic

For people living with HIV. Resources and information about living well with HIV.

For news and media. Latest news and press releases via our media centre.

For healthcare professionals, Information about ViiV medicines and data.